Rani Therapeutics Holdings, Inc.
RANI
$0.508
-$0.0059-1.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -11.51% | -9.55% | -12.37% | -10.68% | -4.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.32% | -23.40% | -26.17% | -15.72% | -3.88% |
| Operating Income | 25.21% | 24.96% | 26.17% | 15.72% | 3.88% |
| Income Before Tax | 17.15% | 16.64% | 22.88% | 12.53% | 0.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.15% | 16.64% | 22.84% | 12.34% | 0.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -24.44% | -21.66% | -24.68% | -13.53% | -2.56% |
| Net Income | 9.92% | 11.63% | 21.00% | 11.14% | -1.05% |
| EBIT | 25.21% | 24.96% | 26.17% | 15.72% | 3.88% |
| EBITDA | 25.80% | 25.59% | 26.78% | 16.25% | 4.31% |
| EPS Basic | 23.58% | 20.86% | 25.22% | 14.27% | 2.54% |
| Normalized Basic EPS | 28.20% | 29.64% | 20.47% | 11.69% | -3.19% |
| EPS Diluted | 23.58% | 20.86% | 25.22% | 14.27% | 2.54% |
| Normalized Diluted EPS | 28.20% | 29.64% | 20.47% | 11.69% | -3.19% |
| Average Basic Shares Outstanding | 17.95% | 11.61% | 5.96% | 3.82% | 3.85% |
| Average Diluted Shares Outstanding | 17.95% | 11.61% | 5.96% | 3.82% | 3.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |